Key facts

Active Substance
Eplontersen
Therapeutic area
Neurology
Decision number
P/0534/2022
PIP number
EMEA-003294-PIP01-22
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of transthyretin amyloidosis (ATTR)
Route(s) of administration
Subcutaneous use
Contact for public enquiries

AstraZeneca AB

E-mail: paediatrics@astrazeneca.com
Tel. +46(8)55324400

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page